Company Overview of TFChem S.A.S.
TFChem S.A.S., a drug-discovery company, develops and markets fluorinated glycomimetic compounds for pharmaceutical and biotechnological companies. The company also develops SGLT 1 and 2 inhibitors for the treatment of diabetes and obesity; and develops a product portfolio in the areas of preservation of biological materials. Its compounds are used in various applications, such as cancer, diabetes, pain and inflammation, cosmetic, dermatology, and cardio-vascular diseases. The company was incorporated in 2009 and is based in Val de Reuil, France. As of March 31, 2011, TFChem S.A.S. operates as a subsidiary of Sirona Biochem Corp.
Voie de l’innovation
Pharma Parc II
Chaussée du Vexin
Val de Reuil, 27100
Founded in 2009
33 2 32 09 01 16
33 2 32 25 07 64
Key Executives for TFChem S.A.S.
Similar Private Companies By Industry
|A.T.O. ZIZINE S.A.S||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact TFChem S.A.S., please visit www.tfchemistry.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.